Upgrade to SI Premium - Free Trial

Seattle Genetics (SGEN) & Astellas Update Phase 1 Data of Investigational Antibody-Drug Conjugate Enfortumab Vedotin

June 4, 2018 6:37 AM
Seattle Genetics, Inc. (NASDAQ: SGEN) and Astellas Pharma Inc. today announced the presentation of updated phase 1 data of enfortumab ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

FDA Management Comments

Next Articles